Valbenazine: First Global Approval

<div><i>Disclosure:</i> The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. E. S. Kim is a salaried employee of Adis, Springer SBM.</div><div><br></div><div>Additional information about this Adis Drug Review can be found<b> <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a>.</b></div><div><br></div><div>Abstract</div><div><br></div><div>Valbenazine (Ingrezza™) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (TD), is at various stages of development in other countries for TD and is in phase 2 development in the USA for Tourette syndrome. This article summarizes the milestones in the development of valbenazine leading to its first global approval in the USA for the treatment of adults with TD.</div><div>Access to the full article can be found <b><a href="http://dx.doi.org/10.1007/s40265-017-0770-9">here</a>.</b></div><div><br></div><div>© Springer International Publishing AG, part of Springer Nature 2017</div><div><br>